GlassScriptPhysician profile
Praveer Kumar
NPI 1255429783
$755.32
in general payments reported to CMS, 2019-2025
17 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $54.13 · 2022: $43.99 · 2023: $33.83 · 2024: $149 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $363.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $125.06 | 2019-2025 | |
| Novo Nordisk INC | $101.58 | 2019-2025 | |
| Amgen INC. | $67.40 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $50.00 | 2019-2020 | |
| Glaxosmithkline, LLC. | $49.39 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Dexcom, INC. | $42.68 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $40.62 | 2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $38.59 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $35.97 | 2023-2025 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $33.46 | 2019 | |
| Merck Sharp & Dohme LLC | $30.84 | 2019-2022 | |
| Amarin Pharma, INC. | $29.55 | 2019 | |
| Lilly USA, LLC | $28.65 | 2023-2025 | Jardiance, Emgality, Mounjaro |
| Abbvie INC. | $27.50 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $20.88 | 2024 | Farxiga |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $20.37 | 2025 | Ultomiris |
| Hikma Pharmaceuticals USA | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Praveer Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.